Lataa...
Population Pharmacokinetics and Exposure‐Response Analyses for CPX‐351 in Patients With Hematologic Malignancies
CPX‐351, a dual‐drug liposomal encapsulation of cytarabine and daunorubicin at a synergistic ratio, is approved in the United States for adults with newly diagnosed therapy‐related acute myeloid leukemia or acute myeloid leukemia with myelodysplasia‐related changes. Population pharmacokinetics analy...
Tallennettuna:
| Julkaisussa: | J Clin Pharmacol |
|---|---|
| Päätekijät: | , , , , |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
John Wiley and Sons Inc.
2018
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6590377/ https://ncbi.nlm.nih.gov/pubmed/30566230 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/jcph.1366 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|